Article
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2011
Woyach Jennifer A, Ruppert Amy S, Heerema Nyla A, Peterson Bercedis L, Gribben John G, Morrison Vicki A, Rai Kanti R, Larson Richard A, Byrd John C
Abstract excerpt
PURPOSE: The addition of rituximab to fludarabine-based regimens in chronic lymphocytic leukemia (CLL) has been shown to produce high response rates with extended remissions. The long-term follow-up of these regimens with respect to progression, survival, risk of secondary leukemia, and impact of genomic risk factors has been limited. METHODS: We report the long-term follow-up of the chemoimmunotherapy trial...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.